Weight loss medications carry risks including nausea, vomiting, pancreatitis, gallbladder disease, and thyroid C-cell tumors (observed in rodent studies
Measurable weight loss typically defined as a reduction of 5% or more in body weight may become apparent between weeks four and twelve, depending on the dose reached and individual factors
A 2025 systematic review of 80 randomized clinical trials of patients taking GLP-1 RAs, published in the Journal of the American Medical Associations JAMA Psychiatry, found that GLP-1 RA treatment in patients with obesity and/or diabetes was not associated with an increased risk of depressive symptoms
and as a matter of fact, can be extremely important for the preference and attitude toward different kinds of food (37, 38)
Constipation responds to increased water and fiber intake
Are GLP-1s Making You Skinny Fat